Carbonaceous nanoparticles (CNP) have distinctive physical and chemical properties that make them useful in a wide range of applications. As the production of these particles increases, there is a growing need to explore their potentially harmful effects due to environmental and occupational exposure. Mounting evidence indicates that toxicological outcomes of CNP exposure may vastly depend on surface properties, size, shape and functionalization. In the current study, we evaluated pulmonary inflammation and systemic immune responses in mice after pulmonary exposure to structurally different CNP: pristine C60 fullerene; TRIS-functionalized C60 (C60-TRIS) and graphene oxide (GO). The inflammagenic potential of the tested CNP was found to be as follows: GO>C60-TRIS>C60, as evidenced by accumulation of PMNs, macrophages and lymphocytes as well as changes in lung permeability and inflammatory cytokine profiles in the lungs on days 1 and 7 post exposure. Further, GO and fullerenes were found to induce reactive oxygen species production by RAW 264.7 macrophages in vitro. To investigate if pulmonary exposure to CNP altered systemic immune reactivity, we tested the proliferative response of spleen T cells of exposed animals. In mice exposed to GO, T cell proliferation was decreased; however, it was increased in fullerene-exposed animals. Co-incubation of OVA-specific B3Z hybridoma T cells with OVA-loaded dendritic cells (DC) exposed to GO or fullerenes resulted in altered IL-2 production by B3Z cells, suggesting that modified T cells responses seen in vivo can be partially attributed to a direct modulation of DC functions by GO. Overall, our study shows the potential of fullerenes and GO to induce pulmonary inflammation.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.